IL6R and Autoimmunity: Despite these encouraging results, efforts to apply IL-6 or IL-6R blockade prospectively with therapeutic intent in clinical trials have lagged behind preclinical data, possibly due to resistance to repurpose these drugs from autoimmunity into the oncology setting.